Icos MAb Hu23F2G will be studied in five Phase II trials; hemorrhagic shock trial commenced in April.
Executive Summary
ICOS MAb Hu23F2G CLINICAL PROGRAM TO INCLUDE FIVE PHASE II TRIALS, the company indicates in a prospectus for a recent public offering. The Icos development program focuses on "early acquisition of Phase II data" through "numerous appropriate Phase II clinical trials in order to increase the likelihood of identifying clinically relevant programs," the prospectus states.